CMS Approves Separate Medicare Payment for InfuSystem Infusion Pumps Under NOPAIN Act

Reuters12-11

CMS Approves Separate Medicare Payment for InfuSystem Infusion Pumps Under NOPAIN Act

InfuSystem Holdings Inc. announced that the Centers for Medicare and Medicaid Services $(CMS)$ has added two electronic infusion pumps used by the company-ICU Medical's CADD-SolisTM and Eitan Medical's SapphireTM-to the list of products qualifying for separate payment under the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act. This CMS decision allows InfuSystem's current and potential Pain Management customers to receive separate reimbursement for these devices when used with covered surgical procedures, starting January 1, 2026, through December 31, 2027. The NOPAIN Act initiative is aimed at promoting non-opioid alternatives for pain management and reducing opioid use in postoperative care. The approval covers products from multiple manufacturers, not just InfuSystem.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InfuSystem Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-056364), on December 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590556369?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 06:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590556369","market":"nz","top_or_hot":-1,"title":"CMS Approves Separate Medicare Payment for InfuSystem Infusion Pumps Under NOPAIN Act","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CMS Approves Separate Medicare Payment for InfuSystem Infusion Pumps Under NOPAIN Act\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        InfuSystem Holdings Inc. announced that the Centers for Medicare and Medicaid Services <a href=\"https://laohu8.com/S/CMS\">$(CMS)$</a> has added two electronic infusion pumps used by the company-ICU Medical's CADD-SolisTM and Eitan Medical's SapphireTM-to the list of products qualifying for separate payment under the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act. This CMS decision allows InfuSystem's current and potential Pain Management customers to receive separate reimbursement for these devices when used with covered surgical procedures, starting January 1, 2026, through December 31, 2027. The NOPAIN Act initiative is aimed at promoting non-opioid alternatives for pain management and reducing opioid use in postoperative care. The approval covers products from multiple manufacturers, not just InfuSystem.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InfuSystem Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-056364), on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMS Approves Separate Medicare Payment for InfuSystem Infusion Pumps Under NOPAIN Act</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMS Approves Separate Medicare Payment for InfuSystem Infusion Pumps Under NOPAIN Act\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 06:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CMS Approves Separate Medicare Payment for InfuSystem Infusion Pumps Under NOPAIN Act\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        InfuSystem Holdings Inc. announced that the Centers for Medicare and Medicaid Services <a href=\"https://laohu8.com/S/CMS\">$(CMS)$</a> has added two electronic infusion pumps used by the company-ICU Medical's CADD-SolisTM and Eitan Medical's SapphireTM-to the list of products qualifying for separate payment under the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act. This CMS decision allows InfuSystem's current and potential Pain Management customers to receive separate reimbursement for these devices when used with covered surgical procedures, starting January 1, 2026, through December 31, 2027. The NOPAIN Act initiative is aimed at promoting non-opioid alternatives for pain management and reducing opioid use in postoperative care. The approval covers products from multiple manufacturers, not just InfuSystem.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InfuSystem Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-056364), on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0240878834.USD","symbol_name":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL5kjMj3:1","article_id":"2590556369","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590556369","pubTimestamp":1765405459,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InfuSystem Holdings Inc. announced that the Centers for Medicare and Medicaid Services  has added two electronic infusion pumps used by the company-ICU Medical's CADD-SolisTM and Eitan Medical's SapphireTM-to the list of products qualifying for separate payment under the Non-Opioids Prevent Addiction in the Nation  Act. This CMS decision allows InfuSystem's current and potential Pain Management customers to receive separate reimbursement for these devices when used with covered surgical procedures, starting January 1, 2026, through December 31, 2027. The NOPAIN Act initiative is aimed at promoting non-opioid alternatives for pain management and reducing opioid use in postoperative care. The approval covers products from multiple manufacturers, not just InfuSystem.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","BK4196":"保健护理服务","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","INFU":"InfuSystems Holdings Inc","ICUI":"ICU医疗","BK4198":"医疗保健用品","SG9999015978.USD":"利安颠覆性创新基金A","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV"},"translate_title":"CMS批准根据NOPAIN法案对InfuSystem输液泵进行单独的Medicare支付","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INFU":0.9,"ICUI":0.9},"content_text":"CMS Approves Separate Medicare Payment for InfuSystem Infusion Pumps Under NOPAIN Act\n    \n\n        InfuSystem Holdings Inc. announced that the Centers for Medicare and Medicaid Services $(CMS)$ has added two electronic infusion pumps used by the company-ICU Medical's CADD-SolisTM and Eitan Medical's SapphireTM-to the list of products qualifying for separate payment under the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act. This CMS decision allows InfuSystem's current and potential Pain Management customers to receive separate reimbursement for these devices when used with covered surgical procedures, starting January 1, 2026, through December 31, 2027. The NOPAIN Act initiative is aimed at promoting non-opioid alternatives for pain management and reducing opioid use in postoperative care. The approval covers products from multiple manufacturers, not just InfuSystem.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InfuSystem Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-056364), on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590556369","isCrawlerRequest":true}